易瑞生物
(300942)
| 流通市值：25.82亿 | | | 总市值：31.63亿 |
| 流通股本：3.27亿 | | | 总股本：4.01亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 36,475,073.45 | 254,106,487.66 | 165,099,285.79 | 112,111,327.49 |
| 营业收入 | 36,475,073.45 | 254,106,487.66 | 165,099,285.79 | 112,111,327.49 |
| 二、营业总成本 | 44,390,455.72 | 332,443,054.25 | 244,638,062.81 | 184,963,695.48 |
| 营业成本 | 9,258,401.03 | 127,232,415.35 | 84,644,515.39 | 68,030,792.11 |
| 税金及附加 | 101,240.55 | 3,676,750.18 | 3,305,422.74 | 846,888.92 |
| 销售费用 | 9,732,419.01 | 56,752,453.15 | 53,006,160.1 | 39,355,577.82 |
| 管理费用 | 12,772,224.71 | 94,432,190.54 | 61,540,272.35 | 44,505,813.3 |
| 研发费用 | 10,280,504.62 | 53,143,295.11 | 48,609,330.98 | 40,507,628.38 |
| 财务费用 | 2,245,665.8 | -2,794,050.08 | -6,467,638.75 | -8,283,005.05 |
| 其中:利息费用 | 5,394,782.25 | 10,628,527.84 | 4,498,644.38 | 3,537,278.3 |
| 其中:利息收入 | 2,818,626.92 | 7,556,944.53 | 6,010,499.29 | 3,957,325.09 |
| 加:公允价值变动收益 | 89,240.29 | 28,041.67 | 152,070.07 | 152,070.07 |
| 加:投资收益 | -1,663,633.85 | -54,112,059.31 | -7,949,168.23 | -5,134,534.8 |
| 资产处置收益 | 177,634.86 | 2,810,213 | 2,588,935.56 | 2,134,806.62 |
| 资产减值损失(新) | - | -56,447,800.58 | -17,030,774.29 | -12,645,004.05 |
| 信用减值损失(新) | 546,959.05 | -3,519,612.74 | -2,526,588.32 | -358,709.22 |
| 其他收益 | 1,422,804.83 | 14,276,597.73 | 9,217,965.42 | 4,910,767.05 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -7,342,377.09 | -175,301,186.82 | -95,086,336.81 | -83,792,972.32 |
| 加:营业外收入 | 12,653.03 | 975,150.24 | 872,079.4 | 757,656.55 |
| 减:营业外支出 | - | 3,472,007.52 | 2,024,544.84 | 959,742.84 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -7,329,724.06 | -177,798,044.1 | -96,238,802.25 | -83,995,058.61 |
| 减:所得税费用 | -55,961.4 | 7,185,311.21 | 2,977,809.62 | -14,319,168.36 |
| 六、净利润 | -7,273,762.66 | -184,983,355.31 | -99,216,611.87 | -69,675,890.25 |
| 持续经营净利润 | -7,273,762.66 | -184,983,355.31 | -99,216,611.87 | -69,675,890.25 |
| 归属于母公司股东的净利润 | -7,111,078.14 | -184,907,769.73 | -99,158,554.33 | -69,632,293.13 |
| 少数股东损益 | -162,684.52 | -75,585.58 | -58,057.54 | -43,597.12 |
| (一)基本每股收益 | -0.02 | -0.46 | -0.25 | -0.17 |
| (二)稀释每股收益 | -0.02 | -0.46 | -0.25 | -0.17 |
| 八、其他综合收益 | -66,277.39 | 400,468.31 | 1,803,253.06 | 2,622,166.44 |
| 归属于母公司股东的其他综合收益 | -66,277.39 | 400,468.31 | 1,803,253.06 | 2,622,166.44 |
| 九、综合收益总额 | -7,340,040.05 | -184,582,887 | -97,413,358.81 | -67,053,723.81 |
| 归属于母公司股东的综合收益总额 | -7,177,355.53 | -184,507,301.42 | -97,355,301.27 | -67,010,126.69 |
| 归属于少数股东的综合收益总额 | -162,684.52 | -75,585.58 | -58,057.54 | -43,597.12 |
| 公告日期 | 2024-04-26 | 2024-04-26 | 2023-10-27 | 2023-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |